Antimicrobial resistance in Neisseria gonorrhoeae and its risk groups in 23 European countries in 2022 within the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP): a retrospective observational study

  15 May 2025

The European Centre for Disease Prevention and Control (ECDC) has been monitoring antimicrobial resistance (AMR) in Neisseria gonorrhoeae since 2009. This study aimed to compare Euro-GASP 2022 data with the most recent data from 2016 to 2019 to identify changes in AMR and risk groups. Results showed that ceftriaxone resistance remained low in 2022, while cefixime resistance decreased. Azithromycin and ciprofloxacin resistance increased, and female gonorrhoea cases increased. The study highlights the urgent need for enhanced AMR surveillance and the need for novel effective antimicrobials for gonorrhoea treatment. The Euro-GASP data is crucial for refining treatment guidelines and mitigating AMR gonococcal strains.

Author(s): Susanne Jacobsson et al
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Your Biweekly Source for Global AMR Insights!

Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.

Don’t miss out on staying ahead in the global AMR movement—subscribe now!

Subscribe
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!